Piper Jaffray Companies Weighs in on Supernus Pharmaceuticals Inc’s FY2019 Earnings (NASDAQ:SUPN)

Supernus Pharmaceuticals Inc (NASDAQ:SUPN) – Analysts at Piper Jaffray Companies lowered their FY2019 EPS estimates for Supernus Pharmaceuticals in a note issued to investors on Wednesday, November 6th. Piper Jaffray Companies analyst D. Amsellem now anticipates that the specialty pharmaceutical company will earn $2.07 per share for the year, down from their prior estimate of $2.09. Piper Jaffray Companies also issued estimates for Supernus Pharmaceuticals’ Q4 2019 earnings at $0.59 EPS, Q1 2020 earnings at $0.21 EPS, Q2 2020 earnings at $0.35 EPS, Q1 2021 earnings at $0.26 EPS, Q2 2021 earnings at $0.38 EPS and Q3 2021 earnings at $0.46 EPS.

Other equities research analysts have also issued reports about the company. TheStreet lowered Supernus Pharmaceuticals from a “b-” rating to a “c+” rating in a research report on Thursday, August 29th. Zacks Investment Research raised Supernus Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday. BidaskClub raised Supernus Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday. Mizuho reaffirmed a “buy” rating on shares of Supernus Pharmaceuticals in a research report on Wednesday, August 7th. Finally, Berenberg Bank lowered Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday. One research analyst has rated the stock with a sell rating, five have issued a hold rating and five have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $46.50.

SUPN stock opened at $21.72 on Friday. The company has a current ratio of 2.72, a quick ratio of 2.53 and a debt-to-equity ratio of 0.70. The firm has a market cap of $1.53 billion, a P/E ratio of 10.60, a P/E/G ratio of 1.02 and a beta of 1.63. Supernus Pharmaceuticals has a 12-month low of $19.35 and a 12-month high of $49.25. The stock’s 50 day simple moving average is $26.80 and its 200 day simple moving average is $30.29.

Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its quarterly earnings results on Tuesday, November 5th. The specialty pharmaceutical company reported $0.54 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.59 by ($0.05). The firm had revenue of $102.14 million for the quarter, compared to analyst estimates of $108.70 million. Supernus Pharmaceuticals had a net margin of 25.92% and a return on equity of 21.80%. The business’s revenue was down .8% on a year-over-year basis. During the same period in the prior year, the company posted $0.52 earnings per share.

In related news, CEO Jack A. Khattar bought 7,200 shares of the company’s stock in a transaction on Friday, August 23rd. The shares were purchased at an average cost of $26.39 per share, with a total value of $190,008.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 6.57% of the stock is owned by company insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Vanguard Group Inc. increased its position in Supernus Pharmaceuticals by 0.9% in the second quarter. Vanguard Group Inc. now owns 5,345,217 shares of the specialty pharmaceutical company’s stock worth $176,873,000 after buying an additional 49,676 shares during the period. Rice Hall James & Associates LLC increased its holdings in shares of Supernus Pharmaceuticals by 35.1% during the second quarter. Rice Hall James & Associates LLC now owns 1,351,286 shares of the specialty pharmaceutical company’s stock valued at $44,714,000 after purchasing an additional 350,905 shares during the period. Macquarie Group Ltd. increased its holdings in shares of Supernus Pharmaceuticals by 8.5% during the second quarter. Macquarie Group Ltd. now owns 1,079,001 shares of the specialty pharmaceutical company’s stock valued at $35,705,000 after purchasing an additional 84,846 shares during the period. Neumeier Poma Investment Counsel LLC increased its holdings in shares of Supernus Pharmaceuticals by 1.1% during the second quarter. Neumeier Poma Investment Counsel LLC now owns 957,401 shares of the specialty pharmaceutical company’s stock valued at $31,680,000 after purchasing an additional 10,170 shares during the period. Finally, Provident Investment Management Inc. increased its holdings in shares of Supernus Pharmaceuticals by 13.8% during the second quarter. Provident Investment Management Inc. now owns 726,333 shares of the specialty pharmaceutical company’s stock valued at $24,034,000 after purchasing an additional 88,099 shares during the period. 99.14% of the stock is currently owned by hedge funds and other institutional investors.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy and migraine.

Featured Article: What are the components of an earnings report?

Earnings History and Estimates for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.